Schwann Cells Accelerate Osteogenesis via the Mif/CD74/FOXO1 Signaling Pathway In Vitro

Abstract

Schwann cells have been found to promote osteogenesis by an unclear molecular mechanism. To better understand how Schwann cells accelerate osteogenesis, RNA-Seq and LC-MS/MS were utilized to explore the transcriptomic and metabolic response of MC3T3-E1 to Schwann cells. Osteogenic differentiation was determined by ALP staining. Lentiviruses were constructed to alter the expression of Mif (macrophage migration inhibitory factor) in Schwann cells. Western blot (WB) analysis was employed to detect the protein expression. The results of this study show that Mif is essential for Schwann cells to promote osteogenesis, and its downstream CD74/FOXO1 is also involved in the promotion of Schwann cells on osteogenesis. Further, Schwann cells regulate amino acid metabolism and lipid metabolism in preosteoblasts. These findings unveil the mechanism for Schwann cells to promote osteogenesis where Mif is a key factor.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Schwann cells have been found to have an important role in osteogenesis. During development, the presence of nerve and Schwann cells in the niche supports osteogenic differentiation of osteoprogenitor cells leading to new bone formation [1]. During bone repair, several studies have found that Schwann cells can be utilized to promote osteogenesis in TEB (tissue-engineered bone) [2, 3]. Besides, Schwann cell precursors have been found to contribute to skeletal formation during embryonic development in mice and zebrafish [4]. Schwann cells were also found to promote osteogenesis in vitro [5]. However, the mechanism of how Schwann cells promote osteogenesis is unclear.

Mif is an important inflammatory cytokine involved in tissue protection and regeneration, such as nerve and muscle [6–8]. It can be synthesized with a variety of cells; stored in the cytoplasm, such as Schwann cells; and released with a specific stimulus, such as bacteria-derived metabolites and hypoxia [9]. Mif has been found to play an important role in the development and repair of bones; however, its role in osteogenesis remains controversial. Discrepancies in the findings may result from stimuli coming from different cells [5, 10].

Above all, this study intends to study the role of Mif in Schwann cells promoting osteogenesis. Besides, the transcriptomic and metabolic response of preosteoblast cells and the correlation between metabolomics and transcriptomics were analyzed, to understand the mechanisms of Schwann cells and its Mif in promoting osteogenesis.

2. Materials and Methods

2.1. Cell Culture

Schwann cells were harvested from the mouse sciatic nerve with the method previously published [11]. 24 hours after initial plating and incubation for 2–3 days to remove fibroblasts, the arabinoside (10^-5 mol/L) was added to the culture medium. The coculture system was established with six-well Transwell clear polyester membrane inserts with 0.4 μm pore size (Costar Corning, USA). $5\ast {10}^4$ Schwann cells were plated on the transwell inserts; $1\ast {10}^5$ MC3T3-E1 cells were plated on the tissue culture plates. MC3T3-E1 was harvested for RNA-Seq and LC-MC/MS after 3 days of coculture.

2.2. Lentiviral Vectors

The Mif overexpression lentivirus and knockdown lentivirus were constructed by Shanghai Genechem Co., Ltd. For the Mif overexpression lentivirus (lv-Mif), the Mif sequence was cloned into the Ubi-MCS-Cherry-SV40-puromycin. For the Mif knockdown lentivirus (sh-Mif), the siRNA sequence of Mif, CCTGCACAGCATCGGCAAGAT, was cloned into the U6-MCS-Ubiquitin-Cherry-IRES-puromycin lentivirus.

2.3. ALP Staining and Activity

To test the differentiation of osteoblast, after 12 days of coculture in commercial kit MC3T3-E1 cell osteogenic differentiation medium (Cyagen, MUXMT-90021), MC3T3-E1 were washed with PBS and stained with the commercial kit according to the manufacturer’s instruction (Sigma, USA). ALP activity was detected by an ALP activity kit (P0321S, Beyotime). Briefly, cells were lysed and incubated with chromogenic substrate and detection buffer at 37°C for 6 mins; the incubation was stopped by stop solution; then, the ALP activity was measured at 405 nm.

2.4. RNA-Seq

RNA-Seq and RNA-Seq analysis were performed as previously reported [12]. To remove the adaptors and low-quality reads, raw reads were firstly trimmed and then mapped to mouse genome with Hisat2 v2.0.5, and gene expression levels were quantified as read counts generated with featureCounts v1.5.0-p3. With DESeq2 R package (1.16.1), differential gene expression was then analyzed.

2.5. Untargeted LC-MS/MS

Untargeted LC-MS/MS analyses were performed with an UHPLC system (Vanquish, Thermo Fisher Scientific) with a UPLC BEH Amide column ($2.1\text{mm}\times 100\text{mm}$, 1.7 μm) coupled to the Q Exactive HFX mass spectrometer (Orbitrap MS, Thermo). The mobile phase consisted of 25 mmol/L ammonium acetate and 25 ammonia hydroxide in water ($\text{pH}=9.75$) (A) and acetonitrile (B). The autosampler temperature was 4°C with an injection volume of 3 μL.

The QE HFX mass spectrometer was utilized for its ability to acquire MS/MS spectra on an information-dependent acquisition (IDA) mode in the control of the acquisition software (Xcalibur, Thermo). The acquisition software in this mode continuously evaluates the full scan MS spectrum. The ESI source conditions were set as the following: 30 Arb for sheath gas flow rate, 25 Arb for Aux gas flow rate, 350°C for capillary temperature, 60000 for full MS resolution, 7500 for MS/MS resolution, 10/30/60 in NCE mode for collision energy, and 3.6 kV (positive) for spray voltage or -3.2 kV (negative), respectively.

The raw data were converted to the mzXML format with ProteoWizard and processed with an in-house program, which was developed with R and based on XCMS for peak detection, extraction, alignment, and integration. Then, an in-house MS2 database (BiotreeDB) was applied in metabolite annotation. The cutoff for annotation was set at 0.3.

2.6. Quantitative Real-Time RT-PCR (qPCR)

Total RNA was purified from cells using TRIzol (Invitrogen, 15596026), reverse-transcribed using Prime Script™ RT Master Mix (TaKaRa, Japan), and subjected to qPCR using Taq SYBR Green Power PCR Master Mix (Invitrogen, A25777) on a CFX96™ real-time system (Bio-Rad). Gapdh was used as an internal control. The primer sequences were the following: Alp forward: CACGTTGACTGTGGTTACTGCTGA and reverse: CCTTGTAACCAGGCCCGTTG; Col1a1 forward: GACATGTTCAGCTTTGTGGACCTC and reverse: GGGACCCTTAGGCCATTGTGTA; Osx forward: TGACTGCCTGCCTAGTGTCTACA and reverse: TGGATGCCCGCCTTGT; Runx2 forward: CATGGCCGGGAATGATGAG and reverse: TGTGAAGACCGTTATGGTCAAAGTG; and Gapdh forward: ATGTGTCCGTCGTGGATCTGA and reverse: ATGCCTGCTTCACCACCTTCTT.

2.7. Western Blot

Pretreated cells were gathered on ice and lysed with RIPA lysis buffer. Proteins were separated on 4%–12% Bis-Tris polyacrylamide gels and transferred to the PVDF membrane. The blots were incubated with primary antibodies overnight at 4°C and then with secondary antibodies. The following primary antibodies were adopted: Actin (Servicebio, GB12001; 1 : 1000); Aldoc (Proteintech, 14884-1-AP, 1 : 5000); CD74 (Bioss, bs-2518R, 1 : 2000); CYP51 (Proteintech, 13431-1-AP, 1 : 5000); EBP (Proteintech, 15518-1-AP, 1 : 1000); ENO2 (Servicebio, GB11376, 1 : 1000); FDFT1 (Proteintech, 13128-1-AP, 1 : 1000); FOXO1 (Servicebio, GB11286; 1: 2000); Gapdh (Proteintech, 60004-1-Ig, 1 : 20000); Gpi1 (Proteintech, 15171-1-AP, 1 : 1000); Hif-1a (Servicebio, GB111339, 1 : 1000); Mif (Proteintech, 26992-1-AP, 1 : 1000); NSDHL (Proteintech, 15111-1-AP, 1 : 1000); PFKL (abcam, ab181064, 1 : 5000); Pgk1 (abcam, ab199438, 1 : 2000); PKM (abcam, ab150377, 1 : 5000); p53 (Proteintech, 10442-1-AP, 1 : 1000); Tpi1 (abcam, ab196618, 1 : 1000).

2.8. Statistical Analysis

GraphPad Prism 8.0.1 (GraphPad Software, LLC.) was utilized for the statistical analysis to quantify ALP activity. The $\text{mean}\pm \text{standard}\text{deviation}$ was recorded for all the experiments. Statistical significance between two groups was assessed with Student’s $t$-test. $P$ values < 0.05 were regarded to be of statistical significance. The content of differential genes and differential metabolites was used to provide transcriptome and metabolome correlations. Spearman correlation analyses were used where $P$ values < 0.05 were regarded to be of statistical significance.

3. Results

3.1. The Transcriptomic Response of Preosteoblast to Schwann Cells

To study the effect of Schwann cells on osteogenesis, we cocultured Schwann cells and MC3T3-E1. Schwann cells were identified and characterized by immunofluorescent staining target its marker S100 and GFAP (Supplementary Figure S1a). As previously published [13, 14], Schwann cells promote osteoblastic differentiation (Figures 1(a)–1(e)). RNA-Seq showed that Schwann cells can regulate the expression of multiple genes in MC3T3-E1 (Figure 1(f)), with 200 transcripts upregulated and 391 transcripts downregulated (Figure 1(g)). Differential gene cluster analysis for all the treatments was conducted (Figure 1(h)). KEGG pathway analysis showed 20 most significantly enriched pathways (Figure 1(i)), including mineral absorption, mainly conducted by osteoclasts. It indicated that Schwann cells could regulate osteoblast/osteoclast coupling and mineralization. Besides, the most enriched pathways also included cell cycle, cell stemness, and signal pathways including p53 and HIF-1 and metabolism such as glycolysis, steroid biosynthesis, amino sugar, and nucleotide sugar metabolism. Then, we studied the metabolic response of preosteoblast to Schwann cells.

[figures omitted; refer to PDF]

3.2. The Metabolic Response of Preosteoblast to Schwann Cells

Untargeted LC-MS/MS were performed to study the metabolic response of preosteoblast to Schwann cells. After being cocultured with Schwann cells, metabolites in MC3T3-E1 have been altered to a great extent (Figure 2(a)). Data acquisition was performed in both positive (POS) and negative (NEG) ion modes (Figures 2(b)–2(d) and Supplemental Figure S2). Chromatograms of all samples in positive (POS) and negative (NEG) ion modes are shown in Figure 2(b) and Supplemental Figure S2. The results of the metabolic pathway analysis are shown via a bubble plot (Figure 2(e)), and the altered metabolites were mainly enriched in “amino acid metabolism”; linoleic acid metabolism (belonging to fatty acid metabolism) was also significantly elevated by Schwann cells. However, there was no significant change in glucose metabolism. After further functional annotation of the differentially accumulated metabolites with the KEGG database, significant metabolite changes were also enriched in amino acid metabolisms (Figure 3, zoom region), such as arginine biosynthesis (NEG, POS); cysteine and methionine metabolism (POS); glycine, serine, and threonine metabolism (POS); and valine, leucine, and isoleucine biosynthesis (NEG).

[figures omitted; refer to PDF]

[figures omitted; refer to PDF]

3.3. Correlations between the Metabolic and Transcriptomic Response of Preosteoblast to Schwann Cells

In further analysis, we studied the correlations between differential metabolites and genes. Differential transcripts were selected from the following pathways: glucose metabolism including glycolysis/gluconeogenesis and fructose and mannose metabolism; fatty acid metabolism including steroid biosynthesis; signaling pathways including p53, HIF-1, and FOXO signaling pathway; and mineral absorption (Supplemental Figure S3). Differential metabolites were taken from the top 16 metabolites with significant differences (Supplemental Figure S3). All differential transcripts and metabolites selected for correlation analysis are shown in Supplemental Figure S3. Correlation analysis was based on the content of differential transcripts and metabolites (Figure 4). Differential metabolites are highly correlated with signaling pathways with the greatest number of significant correlations with the p53 signaling pathway in POS mode and the greatest number of significant correlations with the FOXO1 signaling pathway in NEG mode.

[figure omitted; refer to PDF]

3.4. Schwann Cells Promote Osteogenesis by Mif

Mif is a critical chemokine in Schwann cells during nerve regeneration [15, 16]. Blocking Mif on the Schwann cell greatly reduced neurite outgrowth [17]. Mif has also been found to be promoted on osteoblast differentiation [5]. Then, we probed the role of Mif in Schwann cells promoting osteoblast differentiation. Firstly, to confirm whether Mif can be released from the Schwann cells, we performed ELISA and found a dose-response curve of Mif in response to increasing numbers of SN (Figure 4(d)). These results therefore prove that Mif is a secreted factor from Schwann cells. We then studied the role of Mif in Schwann cells’ promotion of osteogenesis; Mif were overexpressed/downregulated in Schwann cells by lentivirus (Supplemental Figure S4a), and the lentivirus vector did not affect Schwann cells’ function on osteogenesis (Supplemental Figure S4b). We can find that overexpression of Mif could significantly enhance the ability of Schwann cells to promote osteogenesis, while the downregulation of Mif significantly attenuates the ability of Schwann cells to promote osteogenesis (Figures 5(b) and 5(c)).

[figures omitted; refer to PDF]

CD74 is the main receptor for Mif [18]. WB results showed that CD74 expression has been increased in MC3T3-E1 cells by Schwann cells, and the expression of CD74 has been altered following Mif overexpression/downregulation (Figures 5(f) and 5(h)) with a consistent trend. In the RNA-Seq results, Hif-1a, p53, and FOXO1 signaling pathways were the most outstanding pathways involved for Schwann cells to promote osteogenesis. According to WB results, the expression of Hif-1a and p53 was downregulated by Schwann cells, but their expression was inconsistent with Schwann cells and its Mif promoting osteogenesis. The FOXO1 was upregulated by Schwann cells, and its expression changes were consistent with the changes of the Mif/CD74 signal axis when Schwann cells promote osteogenesis. Since the FOXO1 is a transcription factor, the FOXO1 level in the nucleus was also measured, and the factor expression changes were also consistent with the changes of the Mif/CD74 signal axis when Schwann cells promote osteogenesis (Figures 5(g) and 5(h)). Above all, Schwann cells promote osteogenesis through the signaling pathway of Mif/CD74/FOXO1.

According to the RNA-Seq results, there are differential transcripts in glucose metabolism (glycolysis/gluconeogenesis and gluctose and mannose metabolism) and fatty metabolism (steroid biosynthesis). Then, WB were performed to detect the expression response of differential factors in steroid biosynthesis (Figure 5(d)) and glycolysis/gluconeogenesis (Figure 5(e)) to Schwann cells and its Mif. It was found that CYP51, FDFT1, and NSDHL in lipid metabolism were all upregulated by Schwann cells, but only the NSDHL was regulated by Schwann cells-derived Mif. In sugar metabolism, the expression of ^⋅⋅Pgk1 and Tpi1 was upregulated by Schwann cells; ENO2 and PKM were downregulated by Schwann cells; however, all the factors above in glucose metabolism were not regulated by Mif derived from Schwann cells.

4. Discussion

As one of the largest innervated organs [19], peripheral nerve fibers are widely distributed in the bone tissue and most frequently found in metabolically active bone [20]. Schwann cells are glial cells to form myelin in the peripheral nervous system [21]; here, we found that Schwann cells can promote osteogenesis by Mif. Studies undertaken so far provide conflicting evidence concerning the role of Mif in osteogenesis; Onodera et al. generated transgenic mice overexpressing Mif (Mif Tg) with a hybrid promoter composed of a cytomegalovirus (CMV) enhancer and a β-actin/β-globin promoter. They found that bone formation increase in several measures in Mif Tg mice [10]. However, Zheng et al. [5] found that 4-iodo-6-phenylpyrimidine (4-IPP), one of the Mif inhibitors, potentiated osteoblast differentiation and mineralization also through the inhibition of the p65/NF-κB signaling cascade, which implies a negative correlation between Mif and osteogenesis. Mif is a pluripotent protein with diverse functions [22]; with a factor synthesized and stored in the cytoplasm, it will be released and function after activation by diverse stimuli [23], such as bacteria-derived metabolites [24, 25], hypoxia [26, 27], and other inflammatory cytokines [28]. Previous studies have failed to demonstrate a consistent connection between Mif and bone, and the bias of response may result from different sources of Mif.

Further, we found that Schwann cells promote osteogenesis Mif. CD74 is a type II transmembrane protein and a putative Mif receptor that plays a role in Mif-regulated responses [29, 30]. Mun et al. found that the bone phenotype of CD74 KO mice is similar to that of Mif KO mice [31]. We found that CD74 were regulated by Schwann cells and its Mif in MC3T3-E1 cells. FOXO1 belongs to the FOXO family of transcription factors (FoxOs), which can translate environmental signaling into gene expression [32], regulating many cellular processes, including cell survival, proliferation, differentiation, apoptosis, oxidative stress resistance, metabolism, inflammation, and aging [33–36]. FOXO1 promotes osteogenesis; overexpression/depletion of FoxO1 in MC3T3-E1 cells could contribute to promoting/attenuating osteoblast differentiation [37]. The underlying mechanisms are that FOXO1 interacts with Runx2 and ALP gene promoter [38]. Here, we found that FOXO1 is involved in the Schwann cells promoting osteogenesis and regulated by Mif/CD74. FOXO1 is generally involved in lipid metabolism and plays a critical role in the development of lipid-related diseases [39].

We found that Schwann cells could elevate linoleic acid in preosteoblast cells. Further, we found that NSDHL, the enzyme which participated in the steroid synthesis, was elevated by Schwann cells and its Mif. Mif can regulate metabolism in many metabolic diseases, such as glucose metabolism in diabetes; however, its role in bone metabolism has never been thoroughly studied before. NSDHL plays important roles in bone development; defects of the NSDHL gene are the cause of male-lethal mutations bare patches (Bpa) and striated (Str) phenotypes; heterozygous Bpa females are dwarfed and demonstrate abnormal deposits of calcium in tail vertebrae [40, 41]. Linoleic acid is important for the human body to maintain many physiological functions such as the synthesis of phospholipids and other lipid metabolisms. Linoleic acid was found to have the capacity to prevent age-induced bone loss [42] in mice through decreasing adipocyte and increasing osteoblastogenesis [43]. In conclusion, Schwann cells and their Mif can regulate fatty acid metabolism in promoting osteogenesis. The metabolites regulated by Schwann cells were mainly enriched in “amino acid metabolism.” Amino acids are critical precursors for several metabolic pathways, just as aspartate and glutamine are essential for pyrimidine and purine synthesis while providing α-ketoglutarate for the TCA cycle [44]. Through complex transition and inter- and intra-interactions, metabolites form complex networks which still need further study to elucidate.

5. Conclusions

These findings unveil the mechanism for Schwann cells to promote osteogenesis where Schwann cells accelerate osteogenesis via the Mif, and its downstream CD74/FOXO1 is also involved in the promotion of Schwann cells on osteogenesis. Schwann cells and their Mif can regulate amino acid metabolism and fatty acid metabolism in preosteoblasts.

Authors’ Contributions

Jun-Qin Li and Hui-Jie Jiang designed and performed the main study experiments, analyzed the data, and wrote the manuscript; Li Feng purified Schwann cells and modified Schwann cells; Na-Zhi Zhan and Shan-Shan Li performed western blotting experiments; Zi-Jie Chen and Bo-Han Chang performed ALP staining; Xiu-Yun Su and Peng-Zhen Cheng commented on and approved the final manuscript; Guo-Xian Pei and Liu Yang conceived and supervised the research.

References

[1] A. Salhotra, H. N. Shah, B. Levi, M. T. Longaker, "Mechanisms of bone development and repair," Nature Reviews. Molecular Cell Biology, vol. 21 no. 11, pp. 696-711, DOI: 10.1038/s41580-020-00279-w, 2020.

[2] Z. Wu, P. Pu, Z. Su, X. Zhang, L. Nie, Y. Chang, "Schwann cell-derived exosomes promote bone regeneration and repair by enhancing the biological activity of porous Ti6Al4V scaffolds," Biochemical and Biophysical Research Communications, vol. 531 no. 4, pp. 559-565, DOI: 10.1016/j.bbrc.2020.07.094, 2020.

[3] X. Zhang, X. Jiang, S. Jiang, X. Cai, S. Yu, G. Pei, "Schwann cells promote prevascularization and osteogenesis of tissue-engineered bone via bone marrow mesenchymal stem cell-derived endothelial cells," Stem Cell Research & Therapy, vol. 12 no. 1,DOI: 10.1186/s13287-021-02433-3, 2021.

[4] M. Xie, D. Kamenev, M. Kaucka, M. E. Kastriti, B. Zhou, A. V. Artemov, M. Storer, K. Fried, I. Adameyko, V. Dyachuk, A. S. Chagin, "Schwann cell precursors contribute to skeletal formation during embryonic development in mice and zebrafish," Proceedings of the National Academy of Sciences of the United States of America, vol. 116 no. 30, pp. 15068-15073, DOI: 10.1073/pnas.1900038116, 2019.

[5] L. Zheng, J. Gao, K. Jin, Z. Chen, W. Yu, K. Zhu, W. Huang, F. Liu, L. Mei, C. Lou, D. He, "Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP suppresses osteoclast formation and promotes osteoblast differentiation through the inhibition of the NF- κ B signaling pathway," The FASEB Journal, vol. 33 no. 6, pp. 7667-7683, DOI: 10.1096/fj.201802364RR, 2019.

[6] F. Wang, S. Xu, X. Shen, X. Guo, Y. Peng, J. Yang, "Spinal macrophage migration inhibitory factor is a major contributor to rodent neuropathic pain-like hypersensitivity," Anesthesiology, vol. 114 no. 3, pp. 643-659, DOI: 10.1097/ALN.0b013e31820a4bf3, 2011.

[7] I. Kang, R. Bucala, "The immunobiology of MIF: function, genetics and prospects for precision medicine," Nature Reviews Rheumatology, vol. 15 no. 7, pp. 427-437, DOI: 10.1038/s41584-019-0238-2, 2019.

[8] R. M. García Hernández, P. Martín Calvo, R. Blumer, R. de la Cruz RM, Á. M. Pastor Loro, "Functional diversity of motoneurons in the oculomotor system," Proceedings of the National Academy of Sciences of the United States of America, vol. 116 no. 9, pp. 3837-3846, DOI: 10.1073/pnas.1818524116, 2019.

[9] J. B. Bilsborrow, E. Doherty, P. V. Tilstam, R. Bucala, "Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus," Expert Opinion on Therapeutic Targets, vol. 23 no. 9, pp. 733-744, DOI: 10.1080/14728222.2019.1656718, 2019.

[10] S. Onodera, S. Sasaki, S. Ohshima, N. Amizuka, M. Li, N. Udagawa, K. Irie, J. Nishihira, Y. Koyama, A. Shiraishi, H. Tohyama, K. Yasuda, "Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis," Journal of Bone and Mineral Research, vol. 21 no. 6, pp. 876-885, DOI: 10.1359/jbmr.060310, 2006.

[11] J. P. Brockes, G. E. Lemke, D. R. Balzer, "Purification and preliminary characterization of a glial growth factor from the bovine pituitary.," The Journal of Biological Chemistry, vol. 255 no. 18, pp. 8374-8377, DOI: 10.1016/S0021-9258(18)43500-4, 1980.

[12] G. Hu, X. Dong, S. Gong, Y. Song, A. P. Hutchins, H. Yao, "Systematic screening of CTCF binding partners identifies that BHLHE40 regulates CTCF genome-wide distribution and long-range chromatin interactions," Nucleic Acids Research, vol. 48 no. 17, pp. 9606-9620, DOI: 10.1093/nar/gkaa705, 2020.

[13] A. Ozaki, A. Nagai, Y. B. Lee, N. H. Myong, S. U. Kim, "Expression of cytokines and cytokine receptors in human Schwann cells," Neuroreport, vol. 19 no. 1, pp. 31-35, DOI: 10.1097/WNR.0b013e3282f27e60, 2008.

[14] E. A. Horner, J. Kirkham, D. Wood, S. Curran, M. Smith, B. Thomson, X. B. Yang, "Long bone defect models for tissue engineering applications: criteria for choice," Tissue Engineering. Part B, Reviews, vol. 16 no. 2, pp. 263-271, DOI: 10.1089/ten.teb.2009.0224, 2010.

[15] T. Huang, J. Q. Qin, X. K. Huo, L. Yu, S. H. Xiong, D. Y. Liu, S. Z. Zhong, "Changes in content of macrophage migration inhibitory factor secreted by Schwann cells after peripheral nerve injury," Di Yi Jun Yi Da Xue Xue Bao, vol. 22 no. 6, pp. 493-495, 2002.

[16] T. Huang, J. Qin, S. Xiong, L. Yu, X. Huo, H. Liao, J. Li, D. Liu, "Expression of macrophage migration inhibitory factor mRNA in Schwann cells," Zhonghua Wai Ke Za Zhi, vol. 40 no. 9, pp. 699-701, 2002.

[17] P. Ramamurthy, J. B. White, J. Yull Park, R. I. Hume, F. Ebisu, F. Mendez, S. Takayama, K. F. Barald, "Concomitant differentiation of a population of mouse embryonic stem cells into neuron-like cells and Schwann cell-like cells in a slow-flow microfluidic device," Developmental Dynamics, vol. 246 no. 1,DOI: 10.1002/dvdy.24466, 2017.

[18] C. R. Figueiredo, R. A. Azevedo, S. Mousdell, P. T. Resende-Lara, L. Ireland, A. Santos, N. Girola, R. Cunha, M. C. Schmid, L. Polonelli, L. R. Travassos, A. Mielgo, "Blockade of MIF-CD74 signalling on macrophages and dendritic cells restores the antitumour immune response against metastatic melanoma," Frontiers in Immunology, vol. 9,DOI: 10.3389/fimmu.2018.01132, 2018.

[19] H. Chen, B. Hu, X. Lv, S. Zhu, G. Zhen, M. Wan, A. Jain, B. Gao, Y. Chai, M. Yang, X. Wang, R. Deng, L. Wang, Y. Cao, S. Ni, S. Liu, W. Yuan, H. Chen, X. Dong, Y. Guan, H. Yang, X. Cao, "Prostaglandin E2 mediates sensory nerve regulation of bone homeostasis," Nature Communications, vol. 10 no. 1,DOI: 10.1038/s41467-018-08097-7, 2019.

[20] J. M. García-Castellano, P. Díaz-Herrera, J. A. Morcuende, "Is bone a target-tissue for the nervous system? New advances on the understanding of their interactions," The Iowa Orthopaedic Journal, vol. 20, pp. 49-58, 2000.

[21] S. Nishimoto, H. Tanaka, M. Okamoto, K. Okada, T. Murase, H. Yoshikawa, "Methylcobalamin promotes the differentiation of Schwann cells and remyelination in lysophosphatidylcholine-induced demyelination of the rat sciatic nerve," Frontiers in Cellular Neuroscience, vol. 9,DOI: 10.3389/fncel.2015.00298, 2015.

[22] S. S. Jankauskas, D. W. L. Wong, R. Bucala, S. Djudjaj, P. Boor, "Evolving complexity of MIF signaling," Cellular Signalling, vol. 57, pp. 76-88, DOI: 10.1016/j.cellsig.2019.01.006, 2019.

[23] J. Harris, N. Deen, S. Zamani, M. A. Hasnat, "Mitophagy and the release of inflammatory cytokines," Mitochondrion, vol. 41,DOI: 10.1016/j.mito.2017.10.009, 2018.

[24] J. Oteo, G. Bou, F. Chaves, A. Oliver, "Microbiological methods for surveillance of carrier status of multiresistant bacteria," Enfermedades Infecciosas y Microbiología Clínica, vol. 35 no. 10, pp. 667-675, DOI: 10.1016/j.eimc.2015.12.013, 2017.

[25] Z. Baharoglu, D. Mazel, "SOS, the formidable strategy of bacteria against aggressions," FEMS Microbiology Reviews, vol. 38 no. 6, pp. 1126-1145, DOI: 10.1111/1574-6976.12077, 2014.

[26] O. Zis, S. Zhang, K. Dorovini-Zis, L. Wang, W. Song, "Hypoxia signaling regulates macrophage migration inhibitory factor (MIF) expression in stroke," Molecular Neurobiology, vol. 51 no. 1, pp. 155-167, DOI: 10.1007/s12035-014-8727-4, 2015.

[27] S. Zhang, O. Zis, P. T. Ly, Y. Wu, S. Zhang, M. Zhang, F. Cai, R. Bucala, W. C. Shyu, W. Song, "Down-regulation of MIF by NF κ B under hypoxia accelerated neuronal loss during stroke," The FASEB Journal, vol. 28 no. 10, pp. 4394-4407, DOI: 10.1096/fj.14-253625, 2014.

[28] S. Ghosh, N. Jiang, L. Farr, R. Ngobeni, S. Moonah, "Parasite-produced MIF cytokine: role in immune evasion, invasion, and pathogenesis," Frontiers in Immunology, vol. 10,DOI: 10.3389/fimmu.2019.01995, 2019.

[29] H. Su, N. Na, X. Zhang, Y. Zhao, "The biological function and significance of CD74 in immune diseases," Inflammation Research, vol. 66 no. 3, pp. 209-216, DOI: 10.1007/s00011-016-0995-1, 2017.

[30] L. Leng, C. N. Metz, Y. Fang, J. Xu, S. Donnelly, J. Baugh, T. Delohery, Y. Chen, R. A. Mitchell, R. Bucala, "MIF signal transduction initiated by binding to CD74," The Journal of Experimental Medicine, vol. 197 no. 11, pp. 1467-1476, DOI: 10.1084/jem.20030286, 2003.

[31] S. H. Mun, H. Y. Won, P. Hernandez, H. L. Aguila, S. K. Lee, "Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass," Journal of Bone and Mineral Research, vol. 28 no. 4, pp. 948-959, DOI: 10.1002/jbmr.1787, 2013.

[32] A. Ávila-Flores, J. Arranz-Nicolás, I. Mérida, "Transcriptional activity of FOXO transcription factors measured by luciferase assays," FOXO Transcription Factors, pp. 91-102, DOI: 10.1007/978-1-4939-8900-3_8, 2019.

[33] E. C. Genin, N. Caron, R. Vandenbosch, L. Nguyen, B. Malgrange, "Concise review: forkhead pathway in the control of adult neurogenesis," Stem Cells, vol. 32 no. 6, pp. 1398-1407, DOI: 10.1002/stem.1673, 2014.

[34] G. Tuteja, K. H. Kaestner, "SnapShot:Forkhead Transcription Factors I," Cell, vol. 130 no. 6, pp. 1160.e1-1160.e2, DOI: 10.1016/j.cell.2007.09.005, 2007.

[35] S. T. Henderson, T. E. Johnson, "daf-16 integrates developmental and environmental inputs to mediate aging in the nematode Caenorhabditis elegans," Current Biology, vol. 11 no. 24, pp. 1975-1980, DOI: 10.1016/S0960-9822(01)00594-2, 2001.

[36] A. E. Webb, A. Brunet, "FOXO transcription factors: key regulators of cellular quality control," Trends in Biochemical Sciences, vol. 39 no. 4, pp. 159-169, DOI: 10.1016/j.tibs.2014.02.003, 2014.

[37] M. F. Siqueira, S. Flowers, R. Bhattacharya, D. Faibish, Y. Behl, D. N. Kotton, L. Gerstenfeld, E. Moran, D. T. Graves, "FOXO1 modulates osteoblast differentiation," Bone, vol. 48 no. 5, pp. 1043-1051, DOI: 10.1016/j.bone.2011.01.019, 2011.

[38] A. van der Horst, B. M. Burgering, "Stressing the role of FoxO proteins in lifespan and disease," Nature Reviews. Molecular Cell Biology, vol. 8 no. 6, pp. 440-450, DOI: 10.1038/nrm2190, 2007.

[39] Y. Li, Z. Ma, S. Jiang, W. Hu, T. Li, S. Di, D. Wang, Y. Yang, "A global perspective on FOXO1 in lipid metabolism and lipid-related diseases," Progress in Lipid Research, vol. 66, pp. 42-49, DOI: 10.1016/j.plipres.2017.04.002, 2017.

[40] M. E. Lucas, Q. Ma, D. Cunningham, J. Peters, B. Cattanach, M. Bard, B. K. Elmore, G. E. Herman, "Identification of two novel mutations in the murine _Nsdhl_ sterol dehydrogenase gene and development of a functional complementation assay in yeast," Molecular Genetics and Metabolism, vol. 80 no. 1-2, pp. 227-233, DOI: 10.1016/S1096-7192(03)00137-9, 2003.

[41] X. Y. Liu, A. W. Dangel, R. I. Kelley, W. Zhao, P. Denny, M. Botcherby, B. Cattanach, J. Peters, P. R. Hunsicker, A. M. Mallon, M. A. Strivens, R. Bate, W. Miller, M. Rhodes, S. D. Brown, G. E. Herman, "The gene mutated in bare patches and striated mice encodes a novel 3 β -hydroxysteroid dehydrogenase," Nature Genetics, vol. 22 no. 2, pp. 182-187, DOI: 10.1038/9700, 1999.

[42] G. Lin, H. Wang, J. Dai, X. Li, M. Guan, S. Gao, Q. Ding, H. Wang, H. Fang, "Conjugated linoleic acid prevents age-induced bone loss in mice by regulating both osteoblastogenesis and adipogenesis," Biochemical and Biophysical Research Communications, vol. 490 no. 3, pp. 813-820, DOI: 10.1016/j.bbrc.2017.06.122, 2017.

[43] Y. Kim, O. J. Kelly, J. Z. Ilich, "Synergism of α -linolenic acid, conjugated linoleic acid and calcium in decreasing adipocyte and increasing osteoblast cell growth," Lipids, vol. 48 no. 8, pp. 787-802, DOI: 10.1007/s11745-013-3803-5, 2013.

[44] J. R. Oates, M. C. McKell, M. E. Moreno-Fernandez, M. Damen, G. S. Deepe, J. E. Qualls, S. Divanovic, "Macrophage function in the pathogenesis of non-alcoholic fatty liver disease: the mac attack," Frontiers in Immunology, vol. 10,DOI: 10.3389/fimmu.2019.02893, 2019.